Pfizer to combine off-patent drug unit Upjohn with Mylan

pharmafile | July 30, 2019 | News story | Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers 

Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price drug market.

The boards of both Pfizer and Mylan have unanimously approved the deal, which will see Pfizer shareholders own 57% of the yet-to-be-named firm. Shareholders in EpiPen creator Mylan will own the remaining 43% of the newly formed firm.

Pfizer’s Upjohn brings to the table a portfolio of its drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex. The new US-based firm is set to generate $20 billion in sales each year.

Advertisement

Shares in Mylan shot up by 20% on announcement of the deal, while shares in Pfizer fell nearly 2% in early trading on Monday.

The deal could sharpen Pfizer’s focus on branded medicines and vaccines as it streamlines its operations amid the folding of its consumer health business into a joint venture with GSK.

The deal could also see Mylan expand its reach as the firm taps into Upjohn’s existing sales infrastructure in China and other emerging markets around the world. Michael Goettler, currently Group President at Upjohn, will serve as the new company’s CEO.

Louis Goss

Related Content

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

trialy

Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly

Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and …

Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant

Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling …

The Gateway to Local Adoption Series

Latest content